SCHEDULE 13G/A: Dr. D. Victor Perlroth Discloses 11.0% Beneficial Ownership in Kodiak Sciences Inc.
Schedule 13G Filing
Dr. D. Victor Perlroth has filed an amended Schedule 13G, reporting beneficial ownership of 11.0% of Kodiak Sciences Inc.'s common stock as of December 31, 2024.
Summary
- Dr. D. Victor Perlroth beneficially owns an aggregate of 6,164,427 shares of Kodiak Sciences Inc. common stock as of December 31, 2024.
- This ownership represents 11.0% of the total 52,726,916 shares of common stock outstanding as of December 31, 2024.
- Dr. Perlroth holds sole voting power over all 6,164,427 shares.
- Dr. Perlroth holds sole dispositive power over 5,637,427 shares.
- The beneficially owned shares include 2,108,038 shares held directly by Dr. Perlroth.
- It also includes 3,469,389 shares of common stock that Dr. Perlroth has the right to acquire immediately or within sixty days of December 31, 2024, through the exercise of option awards, of which 647,106 shares are unvested but early exercisable and subject to an Issuer right of repurchase as of March 1, 2025.
- An additional 60,000 shares are held by the Perlroth Family Foundation U/A DTD 12/27/2006, for which Dr. Perlroth serves as a trustee.
- Furthermore, 527,000 shares are subject to a voting agreement and proxy, over which Dr. Perlroth exercises sole voting authority.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. While a significant insider stake can be viewed positively by investors, the filing itself does not contain performance data or strategic updates that would significantly shift sentiment beyond a neutral to slightly positive stance.
Positives
- The disclosure of a significant 11.0% stake by an insider like Dr. D. Victor Perlroth can signal strong confidence in the company's future prospects and align management interests with shareholders.
- A substantial insider ownership percentage may reduce agency costs and indicate a commitment to long-term value creation.
Future Outlook
This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing pertains to Kodiak Sciences Inc., a company operating in the biotechnology or pharmaceutical sector, given the nature of its name and the involvement of a medical doctor (M.D.) as a significant shareholder. The filing itself, however, does not provide specific industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure / Voting Rights | Dr. D. Victor Perlroth exercises sole voting authority over 527,000 shares through a voting agreement and proxy, indicating a specific arrangement impacting voting control. | 2024-12-31 | This arrangement centralizes voting power for a portion of shares under Dr. Perlroth, potentially influencing corporate decisions. |
Related Party Transactions
- 60,000 shares are held by the Perlroth Family Foundation U/A DTD 12/27/2006, for which Dr. D. Victor Perlroth is a trustee, indicating a related party holding within the beneficial ownership.
Stakeholder Impact
- Shareholders: The disclosure of a significant insider stake by Dr. D. Victor Perlroth may be perceived positively, suggesting alignment of interests and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-14 | Date the Schedule 13G Amendment No. 6 was signed and filed. |
| 2025-03-01 | Date as of which 647,106 unvested, early exercisable shares are subject to an Issuer right of repurchase. |
Keywords
Kodiak Sciences Inc., D. Victor Perlroth, Schedule 13G, beneficial ownership, common stock, insider ownership, equity stake, voting power, dispositive power
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.